Catalog No.
                        FHJ63110
                        
                                            
                                            
                                            
                                            
                                            
                                            
                                            
                                            Species reactivity
                        
                        Human                        
                                                
                                            Host species
                        
                        Mouse                        
                                                
                                            Isotype
                        
                        IgG1, lambda                        
                                                
                                            Clonality
                        
                        Monoclonal                        
                                                
                                            
                                            Conjugation
                        
                        Unconjugated                        
                                                
                                            
                                            Target
                        
                        SGRF, IL-23-A, IL-23 subunit alpha, Interleukin-23 subunit p19, IL23A, Interleukin-23 subunit alpha, IL-23p19                        
                                                
                                            
                                            Concentration
                        
                        1 mg/ml                        
                                                
                                            Endotoxin level
                        
                        Please contact with the lab for this information.                        
                                                
                                            Purity
                        
                        >95% as determined by SDS-PAGE.                        
                                                
                                            Purification
                        
                        Protein A/G purified from cell culture supernatant.                        
                                                
                                            Accession
                        
                        Q9NPF7                        
                                                
                                            
                                            Applications
                        
                        ELISA, FCM                        
                                                
                                            Form
                        
                        Liquid                        
                                                
                                            Storage buffer
                        
                        0.01M PBS, pH 7.4, 0.09% Sodium azide.                        
                                                
                                            
                                            
                                            
                                            
                                            
                                            
                                            
                                            
                                            
                                            
                                            
                                            Stability and Storage
                        
                        Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.                        
                                                
                                            
                                            
                                                Clone ID
                            SAA0312
                            
                                                    
                                            
                                            
                                        
                 
                
                
                                            An S100A8/A9 Neutralizing Antibody Potently Ameliorates Contact Hypersensitivity and Atopic Dermatitis Symptoms., PMID:39848567
                                            IL-23 inhibition for chronic inflammatory disease., PMID:39461795
                                            The mode of action of IL-23 in experimental inflammatory arthritic pain and disease., PMID:39107827
                                            Chemotherapy-induced high expression of IL23A enhances efficacy of anti-PD-1 therapy in TNBC by co-activating the PI3K-AKT signaling pathway of CTLs., PMID:38902343
                                            IL-23 exerts dominant pathogenic functions in Crohn's disease-ileitis., PMID:38844209
                                            BATF-dependent Th17 cells act through the IL-23R pathway to promote prostate adenocarcinoma initiation and progression., PMID:38833676
                                            Insights into Therapeutic Response Prediction for Ustekinumab in Ulcerative Colitis Using an Ensemble Bioinformatics Approach., PMID:38791570
                                            A Novel Human Interleukin-23A Overexpressing Mouse Model of Systemic Lupus Erythematosus., PMID:38361183
                                            Understanding the impact of risankizumab on keratinocyte-derived IL-23A in a novel organotypic 3D skin model containing IL-23A responsive and IL-17A producing γδ-T-cells., PMID:38284163
                                            Th17-associated cytokines IL-17 and IL-23 in inflamed skin of Darier disease patients as potential therapeutic targets., PMID:37978298
                                            Based on mRNA Sequencing Techniques to Explore the Molecular Mechanism of Buzhong Yiqi Decoction for Autoimmune Thyroiditis., PMID:37070455
                                            Caspase-8 activation in neutrophils facilitates autoimmune kidney vasculitis through regulating CD4+ effector memory T cells., PMID:36505410
                                            A Multicenter, Single-Blind, Case-Control, Immunohistochemical Study of Orbital Tissue in Thyroid Eye Disease., PMID:36128805
                                            Absence of NC14A Domain of COLXVII/BP180 in Mice Results in IL-17‒Associated Skin Inflammation., PMID:35985497
                                            [Expression of Th17 and IL-23 in Peripheral Blood and Their Relationship with Immunophenotype in Patients with Acute Myeloid Leukemia]., PMID:35981362
                                            Biomarkers of disease progression in people with psoriasis: a scoping review., PMID:35482474
                                            Multifaceted Analysis of IL-23A- and/or EBI3-Including Cytokines Produced by Psoriatic Keratinocytes., PMID:34884474
                                            Eczematous drug eruption in patients with psoriasis under anti-interleukin-17A: does interleukin-22 play a key role?, PMID:34862807
                                            Citrullinated human fibrinogen triggers arthritis through an inflammatory response mediated by IL-23/IL-17 immune axis., PMID:34810129
                                            TWEAK functions with TNF and IL-17 on keratinocytes and is a potential target for psoriasis therapy., PMID:34797693
                                            Mucosal IL23A expression predicts the response to Ustekinumab in inflammatory bowel disease., PMID:34448069
                                            Circulating Mir-140 and leptin improve the accuracy of the differential diagnosis between psoriatic arthritis and rheumatoid arthritis: a case-control study., PMID:34380068
                                            Clinical Trials Supporting the Role of the IL-17/IL-23 Axis in Axial Spondyloarthritis., PMID:34149686
                                            Evaluation of Psoriasis Area and Severity Index as a Proxy for Bio-markers of Systemic Disease under Treatment with Tumour Necrosis Factor-alpha and Interleukin 12/23 Antagonists in Patients with Psoriasis: A Retrospective Cohort Study of 186 Treatment Cycles., PMID:33903917
                                            GILZ Regulates the Expression of Pro-Inflammatory Cytokines and Protects Against End-Organ Damage in a Model of Lupus., PMID:33889157
                                            IL-23 skin and joint profiling in psoriatic arthritis: novel perspectives in understanding clinical responses to IL-23 inhibitors., PMID:33243781
                                            Update on risankizumab for the treatment of moderate to severe psoriasis., PMID:32933320
                                            The Effect of Tildrakizumab on Cardiometabolic Risk Factors in Psoriasis by Metabolic Syndrome Status: Post Hoc Analysis of Two Phase 3 Trials (ReSURFACE 1 and ReSURFACE 2)., PMID:32845115
                                            Innate type 1 immune response, but not IL-17 cells control tuberculosis infection., PMID:32798210
                                            The risk of respiratory tract infections in patients with psoriasis treated with interleukin 23 pathway-inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic., PMID:32622891
                                            Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis., PMID:32600737
                                            Optimization of a High-Throughput Cell-Based Screening Strategy to Identify Small-Molecule Inhibitors of IL-23 Signaling., PMID:32484379
                                            IL-15 and IL-23 synergize to trigger Th17 response by CLA+ T cells in psoriasis., PMID:32476200
                                            Antagonistic Peptides That Specifically Bind to the First and Second Extracellular Loops of CCR5 and Anti-IL-23p19 Antibody Reduce Airway Inflammation by Suppressing the IL-23/Th17 Signaling Pathway., PMID:32410846
                                            Effect of adalimumab on the expression profile of mRNA, and protein associated with JAK/STAT signaling pathway in fibroblast exposed to lipopolysaccharide., PMID:32276291
                                            Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial., PMID:32267471
                                            Treatment of psoriasis: janus kinases inhibitors and biologics for the interleukin-23/Th17 axis., PMID:32166932
                                            High interleukin-18 and low FOXP3 mRNAs in peripheral blood of women with severe systemic lupus erythematosus: a cross-sectional study., PMID:32152765
                                            A drug safety evaluation of risankizumab for psoriasis., PMID:32100591
                                            Sequential Histopathological Changes and Cytokine Expressions in Dogs Naturally Infested with Sarcoptes scabiei Mites., PMID:32100229
                                            Autophagy-based unconventional secretion of HMGB1 by keratinocytes plays a pivotal role in psoriatic skin inflammation., PMID:32019420
                                            Ex vivo culture of lesional psoriasis skin for pharmacological testing., PMID:31948839
                                            Short-term transcriptional response to IL-17 receptor-A antagonism in the treatment of psoriasis., PMID:31883845
                                            Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials., PMID:31809827
                                            Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis., PMID:31672037
                                            Infiltrating Myeloid Cells Drive Osteosarcoma Progression via GRM4 Regulation of IL23., PMID:31527131
                                            Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis., PMID:31493397
                                            IL-12/IL-23 neutralization is ineffective for alopecia areata in mice and humans., PMID:31470035
                                            Posttranslational Regulation of IL-23 Production Distinguishes the Innate Immune Responses to Live Toxigenic versus Heat-Inactivated Vibrio cholerae., PMID:31434744